MedTrace Logo

Retrospective Study on the Safety and Therapeutic/Improvement Effects of Intravenous Administration of SHED-CM for ALS (SHED-CAH2023)

NCT06608719 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2024-09-23

No results posted yet for this study

Summary

In this study, we will retrospectively evaluate the safety and efficacy of administering SHED-CM for the treatment of ALS.

Conditions

Interventions

BIOLOGICAL

The study drug is SHED-CM manufactured by U-Factor

Patients diagnosed with ALS were administered SHED-CM

Sponsors & Collaborators

  • Hitonowa Medical

    lead OTHER

Eligibility

Min Age
38 Years
Max Age
81 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-25
Primary Completion
2024-07-01
Completion
2024-07-01

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06608719 on ClinicalTrials.gov